Results 151 to 160 of about 38,272 (314)

Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan

Advances in Therapy
Introduction Sodium–glucose cotransporter 2 inhibitors such as dapagliflozin have been proven effective for slowing chronic kidney disease (CKD) progression in large outcomes trials that mainly included patients with higher levels of albuminuria ...
Navdeep Tangri, Anjay Rastogi, Cassandra Nekeman-Nan, L. S. Hong, Asuka Ozaki, Stefan Franzén, T. Sofue   +6 more
semanticscholar   +1 more source

Cardiac remodelling in type 2 diabetes: Pathophysiological mechanisms and opportunities for multiscale computational modelling and simulation

The Journal of Physiology, EarlyView.
Abstract figure legend Overview of multiscale cardiac remodelling in type 2 diabetes and how to model and simulate these changes using a human‐based, multiscale computational framework. Cardiac remodelling in type 2 diabetes occurs at ionic channel, protein, cellular, tissue and whole‐organ level, affecting the electrophysiological function, mechanical
Ambre Bertrand, Jakub Tomek, Blanca Rodriguez   +2 more
wiley   +1 more source

The Effect of Dapagliflozin on Absence Epilepsy in WAG/Rij Rats

Archives of Epilepsy
Objective: Epilepsy is the most common chronic brain disease that affects millions of people worldwide. In the present study, we investigated the effects of dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, which has been recently ...
Hatice Aygün
doaj   +1 more source

A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro [PDF]

, 2021
Yujie Xing, Biaohu Liu, Shujun Wan, Yi Cheng, Simin Zhou, Yue Sun, Xin-ming Yao, Qiang Hua, Xiang-jian Meng, Jinhan Cheng, Min Zhong, Yan Zhang, Kun Lv, Xiang Kong   +13 more
openalex   +1 more source

Olmesartan‐induced gastritis with no lower gastrointestinal symptoms: A case report

DEN Open, Volume 6, Issue 1, April 2026.
Abstract A 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa. A gastric biopsy revealed inflammatory cell infiltration.
Satoshi Kosaka, Miki Kamiyama, Masahiro Ochi   +2 more
wiley   +1 more source

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/− Mice

Mediators of Inflammation, 2016
Background. Our study aimed to observe the effect of sodium glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin on diabetic atherosclerosis and investigate the subsequent mechanism. Methods.
Weiling Leng, Xinshou Ouyang, Xiaotian Lei, Mingxia Wu, Liu Chen, Qinan Wu, Wuquan Deng, Ziwen Liang   +7 more
doaj   +1 more source

Circulating Profiles of the Bile Acid Metabolomics in Patients With Polycystic Ovary Syndrome Treated With Metformin or Canagliflozin

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 2, February 2026.
ABSTRACT Objective Bile acids are indispensable modulators in the development of polycystic ovary syndrome (PCOS). Our previous study identified that metformin and canagliflozin have similar efficacy in patients with PCOS combined with insulin resistance (IR).
Qi Yan, Meili Cai, Nan Wang, Wenhao Wu, Hua Zhang, Yikun Zhu, Jing Luo, Manna Zhang, Jin Li   +8 more
wiley   +1 more source

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DAPAGLIFLOZIN AND METFORMIN IN PHARMACEUTICAL DOSAGE FORM

, 2023

openalex   +1 more source

Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy

BMC Cardiovascular Disorders
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have beneficial effects in heart failure (HF), including reverse remodelling, but the mechanisms by which these benefits are conferred are unclear.
A. Dihoum, Alexander J M Brown, R. McCrimmon, Chim C Lang, I. Mordi   +4 more
semanticscholar   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source